Pfizer in talks on $5 billion acquisition: media

A man walks past the Pfizer logo on the drug maker's headquarters in New York
A man walks past the Pfizer logo on the drug maker’s headquarters in New York.
Photo: SPENCER PLATT / GETTY IMAGES NORTH AMERICA/Getty Images via AFP/File
Source: AFP

American drugmaker Pfizer is close to a deal to purchase Global Blood Therapeutics, which manufactures a recently approved drug against sickle-cell anemia, for $5 billion, the Wall Street Journal has reported.

Pfizer, one of the top makers of Covid-19 vaccines, hopes to conclude talks with GBT within days, the newspaper said Friday, citing people close to the negotiations.

But it said other takeover candidates remain in the running.

GBT’s sickle-cell treatment, marketed as Oxbryta, was authorized for those over 12 years old in 2019 but gained federal approval in December for children aged four to 11. The blood disorder affects millions.

Sales of Oxbryta helped the laboratory generate first-quarter turnover of $55 million (up 41 percent), while the company registered a net loss of $81.4 million.

GBT, which is based in San Francisco, California, is to publish its second-quarter numbers on Monday.

Read also

Strong N.America sales boost Starbucks results despite China hit

PAY ATTENTION: Share your outstanding story with our editors! Please reach us through info@corp.legit.ng!

Pfizer, for its part, saw its second-quarter turnover jump by 47 percent — to a record $27.74 billion — boosted by sales of its Covid vaccine and pills.

Its net profit soared by 78 percent, to $9.9 billion.

GBT shares on the New York Stock Exchange were up 33.03 percent at the close on Friday, at $63.84, for a market capitalization of more than $4 billion.

Pfizer shares slipped by 1.18 percent, to $49.27.

Source: AFP

Leave a Reply

Your email address will not be published.

Copyright DG Obvious Media 2022 : (Powered by DGNETWORK GROUP www.dgnetwork.org/services)